首页> 美国卫生研究院文献>Harm Reduction Journal >Abuse risks and routes of administration of different prescription opioid compounds and formulations
【2h】

Abuse risks and routes of administration of different prescription opioid compounds and formulations

机译:不同处方阿片类药物化合物和制剂的滥用风险和给药途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundEvaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mitigation Strategies (REMS) for prescription opioid analgesics will require baseline descriptions of abuse patterns of existing opioid analgesics, including the relative risk of abuse of existing prescription opioids and characteristic patterns of abuse by alternate routes of administration (ROAs). This article presents, for one population at high risk for abuse of prescription opioids, the unadjusted relative risk of abuse of hydrocodone, immediate release (IR) and extended release (ER) oxycodone, methadone, IR and ER morphine, hydromorphone, IR and ER fentanyl, IR and ER oxymorphone. How relative risks change when adjusted for prescription volume of the products was examined along with patterns of abuse via ROAs for the products.
机译:背景处方阿片类镇痛药的防篡改制剂(TRF)以及全类别风险评估和缓解策略(REMS)的评估将要求对现有阿片类镇痛药的滥用方式进行基线描述,包括滥用现有处方阿片类药物的相对风险以及滥用阿片类药物的特征性方式替代管理途径(ROA)。本文介绍了对于一个滥用处方阿片类药物的高风险人群来说,滥用氢可酮,立即释放(IR)和延长释放(ER)羟考酮,美沙酮,IR和ER吗啡,氢吗啡酮,IR和ER的未调整相对风险芬太尼,IR和ER羟吗啡酮。研究了根据产品的处方量进行调整后相对风险如何变化,以及通过ROA滥用产品的方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号